Loading…

A class of carbonic anhydrase I - selective activators

A series of ureido and bis-ureido derivatives were prepared by reacting histamine with alkyl/aryl-isocyanates or di-isocyanates. The obtained derivatives were assayed as activators of the enzyme carbonic anhydrase (CA, EC 4.2.1.1), due to the fact that histamine itself has this biological activity....

Full description

Saved in:
Bibliographic Details
Published in:Journal of enzyme inhibition and medicinal chemistry 2017-01, Vol.32 (1), p.37-46
Main Authors: Licsandru, Erol, Tanc, Muhammet, Kocsis, Istvan, Barboiu, Mihail, Supuran, Claudiu T.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c736t-70fcf5143676930eacc4c014ded47b76d3d0365b675a06ce10e801031cdce5cc3
cites cdi_FETCH-LOGICAL-c736t-70fcf5143676930eacc4c014ded47b76d3d0365b675a06ce10e801031cdce5cc3
container_end_page 46
container_issue 1
container_start_page 37
container_title Journal of enzyme inhibition and medicinal chemistry
container_volume 32
creator Licsandru, Erol
Tanc, Muhammet
Kocsis, Istvan
Barboiu, Mihail
Supuran, Claudiu T.
description A series of ureido and bis-ureido derivatives were prepared by reacting histamine with alkyl/aryl-isocyanates or di-isocyanates. The obtained derivatives were assayed as activators of the enzyme carbonic anhydrase (CA, EC 4.2.1.1), due to the fact that histamine itself has this biological activity. Although inhibition of CAs has pharmacological applications in the field of antiglaucoma, anticonvulsant, anticancer, and anti-infective agents, activation of these enzymes is not yet properly exploited pharmacologically for cognitive enhancement or Alzheimer's disease treatment, conditions in which a diminished CA activity was reported. The ureido/bis-ureido histamine derivatives investigated here showed activating effects only against the cytosolic human (h) isoform hCA I, having no effect on the widespread, physiologically dominant isoform hCA II. This is the first report in which CA I-selective activators were identified. Such compounds may constitute interesting tools for better understanding the physiological/pharmacological effects connected to activation of this widespread CA isoform, whose physiological function is not fully understood.
doi_str_mv 10.1080/14756366.2016.1232254
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_14756366_2016_1232254</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_c867c15dab3f42928f04c8b67ce5d006</doaj_id><sourcerecordid>2195235091</sourcerecordid><originalsourceid>FETCH-LOGICAL-c736t-70fcf5143676930eacc4c014ded47b76d3d0365b675a06ce10e801031cdce5cc3</originalsourceid><addsrcrecordid>eNp9kk2P0zAQhiMEYpeFnwCKxAUOKeNv54K2WgFbqRIXOFvO2NmmSuPFTov673FIt2L3wGms8TvPjD1vUbwlsCCg4RPhSkgm5YICkQtCGaWCPysup3wlmeLPz2cpL4pXKW0BKKGEvywuqFK1rpW6LOSyxN6mVIa2RBubMHRY2mFzdNEmX67Kqky-9zh2B1_aKdgxxPS6eNHaPvk3p3hV_Pz65cfNbbX-_m11s1xXqJgcKwUttoJwJpWsGXiLyBEId95x1SjpmAMmRSOVsCDRE_AaCDCCDr1AZFfFaua6YLfmPnY7G48m2M78TYR4Z2wcO-y9QS0VEuFsw1pOa6pb4KgzOpMcgMyszzPrft_sfG4wjNH2j6CPb4ZuY-7Cwcg8EmiSAR9nwOZJ2e1ybaZc3oQimurDpP1wahbDr71Po9l1CX3f28GHfTJEM5H3UXOdpe-fSLdhH4f8rYaSWtAsrCegmFUYQ0rRt-cJCJjJEebBEWZyhDk5Ite9-_fV56oHC2TB9SzohjbEnf0dYu_MaI99iG20A3bJsP_3-AP8_cJv</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2195235091</pqid></control><display><type>article</type><title>A class of carbonic anhydrase I - selective activators</title><source>Taylor &amp; Francis_OA刊</source><source>PubMed Central</source><creator>Licsandru, Erol ; Tanc, Muhammet ; Kocsis, Istvan ; Barboiu, Mihail ; Supuran, Claudiu T.</creator><creatorcontrib>Licsandru, Erol ; Tanc, Muhammet ; Kocsis, Istvan ; Barboiu, Mihail ; Supuran, Claudiu T.</creatorcontrib><description>A series of ureido and bis-ureido derivatives were prepared by reacting histamine with alkyl/aryl-isocyanates or di-isocyanates. The obtained derivatives were assayed as activators of the enzyme carbonic anhydrase (CA, EC 4.2.1.1), due to the fact that histamine itself has this biological activity. Although inhibition of CAs has pharmacological applications in the field of antiglaucoma, anticonvulsant, anticancer, and anti-infective agents, activation of these enzymes is not yet properly exploited pharmacologically for cognitive enhancement or Alzheimer's disease treatment, conditions in which a diminished CA activity was reported. The ureido/bis-ureido histamine derivatives investigated here showed activating effects only against the cytosolic human (h) isoform hCA I, having no effect on the widespread, physiologically dominant isoform hCA II. This is the first report in which CA I-selective activators were identified. Such compounds may constitute interesting tools for better understanding the physiological/pharmacological effects connected to activation of this widespread CA isoform, whose physiological function is not fully understood.</description><identifier>ISSN: 1475-6366</identifier><identifier>EISSN: 1475-6374</identifier><identifier>DOI: 10.1080/14756366.2016.1232254</identifier><identifier>PMID: 27798977</identifier><language>eng</language><publisher>England: Taylor &amp; Francis</publisher><subject>Alzheimer's disease ; Anchoring to zinc-coordinated water ; Animals ; Anticonvulsants ; Biological activity ; carbonic anhydrase ; Carbonic anhydrase I ; Carbonic Anhydrase I - chemistry ; Carbonic Anhydrase I - drug effects ; Carbonic Anhydrase I - metabolism ; Chemical Sciences ; Cognitive ability ; Crystallography, X-Ray ; Enzyme Activators - pharmacology ; Histamine ; Humans ; inhibition mechanism ; inhibitors ; Isocyanates ; Neurodegenerative diseases ; occlusion of the active site entrance ; out of the active site binding ; Physiology ; Protein Conformation ; Proton Magnetic Resonance Spectroscopy ; Spectrometry, Mass, Electrospray Ionization</subject><ispartof>Journal of enzyme inhibition and medicinal chemistry, 2017-01, Vol.32 (1), p.37-46</ispartof><rights>2016 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group 2016</rights><rights>2016 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/Licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Attribution</rights><rights>2016 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group 2016 The Author(s).</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c736t-70fcf5143676930eacc4c014ded47b76d3d0365b675a06ce10e801031cdce5cc3</citedby><cites>FETCH-LOGICAL-c736t-70fcf5143676930eacc4c014ded47b76d3d0365b675a06ce10e801031cdce5cc3</cites><orcidid>0000-0003-0042-9483</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010081/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010081/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27501,27923,27924,53790,53792,59142,59143</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27798977$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.umontpellier.fr/hal-01671828$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Licsandru, Erol</creatorcontrib><creatorcontrib>Tanc, Muhammet</creatorcontrib><creatorcontrib>Kocsis, Istvan</creatorcontrib><creatorcontrib>Barboiu, Mihail</creatorcontrib><creatorcontrib>Supuran, Claudiu T.</creatorcontrib><title>A class of carbonic anhydrase I - selective activators</title><title>Journal of enzyme inhibition and medicinal chemistry</title><addtitle>J Enzyme Inhib Med Chem</addtitle><description>A series of ureido and bis-ureido derivatives were prepared by reacting histamine with alkyl/aryl-isocyanates or di-isocyanates. The obtained derivatives were assayed as activators of the enzyme carbonic anhydrase (CA, EC 4.2.1.1), due to the fact that histamine itself has this biological activity. Although inhibition of CAs has pharmacological applications in the field of antiglaucoma, anticonvulsant, anticancer, and anti-infective agents, activation of these enzymes is not yet properly exploited pharmacologically for cognitive enhancement or Alzheimer's disease treatment, conditions in which a diminished CA activity was reported. The ureido/bis-ureido histamine derivatives investigated here showed activating effects only against the cytosolic human (h) isoform hCA I, having no effect on the widespread, physiologically dominant isoform hCA II. This is the first report in which CA I-selective activators were identified. Such compounds may constitute interesting tools for better understanding the physiological/pharmacological effects connected to activation of this widespread CA isoform, whose physiological function is not fully understood.</description><subject>Alzheimer's disease</subject><subject>Anchoring to zinc-coordinated water</subject><subject>Animals</subject><subject>Anticonvulsants</subject><subject>Biological activity</subject><subject>carbonic anhydrase</subject><subject>Carbonic anhydrase I</subject><subject>Carbonic Anhydrase I - chemistry</subject><subject>Carbonic Anhydrase I - drug effects</subject><subject>Carbonic Anhydrase I - metabolism</subject><subject>Chemical Sciences</subject><subject>Cognitive ability</subject><subject>Crystallography, X-Ray</subject><subject>Enzyme Activators - pharmacology</subject><subject>Histamine</subject><subject>Humans</subject><subject>inhibition mechanism</subject><subject>inhibitors</subject><subject>Isocyanates</subject><subject>Neurodegenerative diseases</subject><subject>occlusion of the active site entrance</subject><subject>out of the active site binding</subject><subject>Physiology</subject><subject>Protein Conformation</subject><subject>Proton Magnetic Resonance Spectroscopy</subject><subject>Spectrometry, Mass, Electrospray Ionization</subject><issn>1475-6366</issn><issn>1475-6374</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9kk2P0zAQhiMEYpeFnwCKxAUOKeNv54K2WgFbqRIXOFvO2NmmSuPFTov673FIt2L3wGms8TvPjD1vUbwlsCCg4RPhSkgm5YICkQtCGaWCPysup3wlmeLPz2cpL4pXKW0BKKGEvywuqFK1rpW6LOSyxN6mVIa2RBubMHRY2mFzdNEmX67Kqky-9zh2B1_aKdgxxPS6eNHaPvk3p3hV_Pz65cfNbbX-_m11s1xXqJgcKwUttoJwJpWsGXiLyBEId95x1SjpmAMmRSOVsCDRE_AaCDCCDr1AZFfFaua6YLfmPnY7G48m2M78TYR4Z2wcO-y9QS0VEuFsw1pOa6pb4KgzOpMcgMyszzPrft_sfG4wjNH2j6CPb4ZuY-7Cwcg8EmiSAR9nwOZJ2e1ybaZc3oQimurDpP1wahbDr71Po9l1CX3f28GHfTJEM5H3UXOdpe-fSLdhH4f8rYaSWtAsrCegmFUYQ0rRt-cJCJjJEebBEWZyhDk5Ite9-_fV56oHC2TB9SzohjbEnf0dYu_MaI99iG20A3bJsP_3-AP8_cJv</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Licsandru, Erol</creator><creator>Tanc, Muhammet</creator><creator>Kocsis, Istvan</creator><creator>Barboiu, Mihail</creator><creator>Supuran, Claudiu T.</creator><general>Taylor &amp; Francis</general><general>Taylor &amp; Francis Ltd</general><general>Informa Healthcare</general><general>Taylor &amp; Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-0042-9483</orcidid></search><sort><creationdate>20170101</creationdate><title>A class of carbonic anhydrase I - selective activators</title><author>Licsandru, Erol ; Tanc, Muhammet ; Kocsis, Istvan ; Barboiu, Mihail ; Supuran, Claudiu T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c736t-70fcf5143676930eacc4c014ded47b76d3d0365b675a06ce10e801031cdce5cc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Alzheimer's disease</topic><topic>Anchoring to zinc-coordinated water</topic><topic>Animals</topic><topic>Anticonvulsants</topic><topic>Biological activity</topic><topic>carbonic anhydrase</topic><topic>Carbonic anhydrase I</topic><topic>Carbonic Anhydrase I - chemistry</topic><topic>Carbonic Anhydrase I - drug effects</topic><topic>Carbonic Anhydrase I - metabolism</topic><topic>Chemical Sciences</topic><topic>Cognitive ability</topic><topic>Crystallography, X-Ray</topic><topic>Enzyme Activators - pharmacology</topic><topic>Histamine</topic><topic>Humans</topic><topic>inhibition mechanism</topic><topic>inhibitors</topic><topic>Isocyanates</topic><topic>Neurodegenerative diseases</topic><topic>occlusion of the active site entrance</topic><topic>out of the active site binding</topic><topic>Physiology</topic><topic>Protein Conformation</topic><topic>Proton Magnetic Resonance Spectroscopy</topic><topic>Spectrometry, Mass, Electrospray Ionization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Licsandru, Erol</creatorcontrib><creatorcontrib>Tanc, Muhammet</creatorcontrib><creatorcontrib>Kocsis, Istvan</creatorcontrib><creatorcontrib>Barboiu, Mihail</creatorcontrib><creatorcontrib>Supuran, Claudiu T.</creatorcontrib><collection>Taylor &amp; Francis_OA刊</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Journal of enzyme inhibition and medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Licsandru, Erol</au><au>Tanc, Muhammet</au><au>Kocsis, Istvan</au><au>Barboiu, Mihail</au><au>Supuran, Claudiu T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A class of carbonic anhydrase I - selective activators</atitle><jtitle>Journal of enzyme inhibition and medicinal chemistry</jtitle><addtitle>J Enzyme Inhib Med Chem</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>32</volume><issue>1</issue><spage>37</spage><epage>46</epage><pages>37-46</pages><issn>1475-6366</issn><eissn>1475-6374</eissn><abstract>A series of ureido and bis-ureido derivatives were prepared by reacting histamine with alkyl/aryl-isocyanates or di-isocyanates. The obtained derivatives were assayed as activators of the enzyme carbonic anhydrase (CA, EC 4.2.1.1), due to the fact that histamine itself has this biological activity. Although inhibition of CAs has pharmacological applications in the field of antiglaucoma, anticonvulsant, anticancer, and anti-infective agents, activation of these enzymes is not yet properly exploited pharmacologically for cognitive enhancement or Alzheimer's disease treatment, conditions in which a diminished CA activity was reported. The ureido/bis-ureido histamine derivatives investigated here showed activating effects only against the cytosolic human (h) isoform hCA I, having no effect on the widespread, physiologically dominant isoform hCA II. This is the first report in which CA I-selective activators were identified. Such compounds may constitute interesting tools for better understanding the physiological/pharmacological effects connected to activation of this widespread CA isoform, whose physiological function is not fully understood.</abstract><cop>England</cop><pub>Taylor &amp; Francis</pub><pmid>27798977</pmid><doi>10.1080/14756366.2016.1232254</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-0042-9483</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1475-6366
ispartof Journal of enzyme inhibition and medicinal chemistry, 2017-01, Vol.32 (1), p.37-46
issn 1475-6366
1475-6374
language eng
recordid cdi_crossref_primary_10_1080_14756366_2016_1232254
source Taylor & Francis_OA刊; PubMed Central
subjects Alzheimer's disease
Anchoring to zinc-coordinated water
Animals
Anticonvulsants
Biological activity
carbonic anhydrase
Carbonic anhydrase I
Carbonic Anhydrase I - chemistry
Carbonic Anhydrase I - drug effects
Carbonic Anhydrase I - metabolism
Chemical Sciences
Cognitive ability
Crystallography, X-Ray
Enzyme Activators - pharmacology
Histamine
Humans
inhibition mechanism
inhibitors
Isocyanates
Neurodegenerative diseases
occlusion of the active site entrance
out of the active site binding
Physiology
Protein Conformation
Proton Magnetic Resonance Spectroscopy
Spectrometry, Mass, Electrospray Ionization
title A class of carbonic anhydrase I - selective activators
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T13%3A12%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20class%20of%20carbonic%20anhydrase%20I%20-%20selective%20activators&rft.jtitle=Journal%20of%20enzyme%20inhibition%20and%20medicinal%20chemistry&rft.au=Licsandru,%20Erol&rft.date=2017-01-01&rft.volume=32&rft.issue=1&rft.spage=37&rft.epage=46&rft.pages=37-46&rft.issn=1475-6366&rft.eissn=1475-6374&rft_id=info:doi/10.1080/14756366.2016.1232254&rft_dat=%3Cproquest_cross%3E2195235091%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c736t-70fcf5143676930eacc4c014ded47b76d3d0365b675a06ce10e801031cdce5cc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2195235091&rft_id=info:pmid/27798977&rfr_iscdi=true